Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799065 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Advanced Solid Tumors, sponsored by Accent Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT06799065 is a Phase 1 study of Ovarian Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Accent Therapeutics. The registered enrollment target is 90 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06799065, a Phase 1 study of Ovarian Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Accent Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Conditions Studied
Interventions
- DRUG ATX-295
Study Locations (5)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799065
The ClinicalTrials.gov registry entry for NCT06799065 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Accent Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which ATX-295 is the first listed.
NCT06799065 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06799065 about?
NCT06799065 is a clinical study titled "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer". The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
What is the current status of trial NCT06799065?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-03-21. Estimated completion is 2027-08-30.
What conditions does trial NCT06799065 study?
This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumors, Triple Negative Breast Cancer, Breast Cancer Recurrent, High-grade Serous Ovarian Carcinoma.
What interventions are being tested in trial NCT06799065?
The interventions under investigation include: ATX-295 (DRUG).
Who is sponsoring clinical trial NCT06799065?
This trial is sponsored by Accent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799065 being conducted?
This trial has 5 study locations across Florida, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.